ArticlesArchiveAboutEditorial BoardAuthor Guidelines
Call for papersThe 2026 special issue on Climate & Health is open for submissions.Learn more
JCT is an international journal dedicated to the latest advancements in cancer therapy. The goal of this journal is to provide a platform for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in cancer related problems. All manuscripts must be prepared in En…
Aravindh S. Anand, Mintu Mathew Abraham, Jayalekshmi Velayudhan
Background: Bevacizumab is a recombinant humanized monoclonal antibody which targets Vasculoendothelial growth factor (VEGF)-A and prevents its binding to VEGF receptor 2 (VEGFR 2). It is approved in the first and second line treatment of metastatic colorecta…
Irtiza Hasan, Tasnuva Rashid
Clinical communication is a multidimensional concept, which encompasses the core of effective clinical practice. Communication in cancer patients is particularly challenging and yet a less focused area in cancer care. Various barriers and challenges in commun…
Ahmed A. S. Salem, Mahoud H. El Shoieby, Amr F. Mourad, Amr F. Mourad, Hosam El-Din Galal Mohammad
Purpose: To highlight the role of multi-detector computed tomography in evaluation of small intestinal neoplastic lesions. Patient and Methods: Thirty patients suspected to have small bowel neaoplasms were examined with 64 MDCT and underwent surgical explorat…
Aaron J. Smith, John Oertle, Dan Warren, Dino Prato
Quercetin is a multifaceted dietary flavonoid with a multitude of biologic activities that can be used to treat various ailments. These include cancer, bacterial and viral infections, cardiovascular disease, and diabetes. A greater emphasis on cancer is discu…
Joana de Castro Rocha, Isabel Paiva, Ana Rita Cruz
Histiocytic sarcoma is an extremely rare and very aggressive malignancy, with poor prognosis. The cases described in the literature are few and the treatment is not currently considered consensual. The clinical presentation is very variable. Its characterizat…
Takanori Ayabe, Masaki Tomita, Eiichi Chosa, Kosuke Mori, Kunihide Nakamura
Background: We have developed a new next-generation intrapleural hyperthermic chemotherapy (IPHC) for non-small cell lung cancer with dissemination, which is a hybrid chemotherapy combined with oral S-1 medication plus conventional cisplatin-based IPHC. We no…
Hala Aziz Shokralla, Ahmed Elsayed Fathalla, Nevine F. H. Sidhom
Background: Primary non-Hodgkin’s lymphoma (PONHL) of the ovary is rare disease. Ovarian involvement by NHL is usually secondary, as a part of systemic disease. It is frequently diagnosed as ovarian carcinoma which causes a significant delay in diagnosis and…
M. A. Nezami, Aron Gould Simon, Geoffrey Bartholomeusz
Bile duct cancer is a rare form of cancer, with approximately 2000 new cases diagnosed in the United States each year. The prognosis of this disease is very grave, especially in the form of intrahepatic (IHCC), as there is no person with stage four who lives…
Maxwell Omabe, Kenneth Nwobini Omabe, Clement Ademola Famurewa, Alberta Egwu Okorocha, Grace Maxwell Omabe
Prostate cancer (PCa) represents the most frequent urologic diagnosis in elderly males. We have previously shown that exposure of prostate to lipopolysaccharide (LPS) promotes cancer risk. We investigated the effect of non-selective cyclooxygenase (COX) inhib…
Susan Tsai, Kathleen K. Christians, Ben George, Paul Ritch, Kiyoko Oshima, Parag Tolat, Ashley Krepline, Beth A. Erickson, Douglas B. Evans
The majority of patients with localized pancreatic cancer (PC) who undergo surgery followed by adjuvant therapy will develop metastatic disease, suggesting that surgery alone is not sufficient for cure and micrometastases are present even when are not clinica…
No articles in this issue.
JCT is an international journal dedicated to the latest advancements in cancer therapy. The goal of this journal is to provide a platform for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in cancer related problems. All manuscripts must be prepared in En… All articles are open access under a CC BY 4.0 licence, with authors retaining copyright.
Authors submit their manuscript, metadata, and declarations through the portal. There is no submission fee.
The editorial office screens the manuscript for scope, completeness, and formatting before assigning a handling editor.
At least two independent reviewers evaluate the manuscript under single-blind review. Where revisions are required, authors respond point by point.
On acceptance the article processing charge is invoiced and the CC BY 4.0 copyright handover is signed.
The article is copyedited, typeset, and given a DOI, then publishes open access with a permanent link.
Manuscripts must be original and not under consideration elsewhere. Submit in Microsoft Word or LaTeX with figures at 300 dpi minimum. Structure research articles as Abstract, Introduction, Methods, Results, Discussion, and References.
Use the journal's numbered (Vancouver) reference style. Cite sources consecutively in the order they appear, and ensure every reference is complete and retrievable.
Declare all funding sources, conflicts of interest, and ethical approvals (including informed consent and animal-care statements where applicable).